What is SSO2 Therapy?
According to the American Heart Association, every year nearly 800,000 people in the U.S have a heart attack. Although PCI (angioplasty and stenting) has been the standard of care in treating AMI for 25 years, many patients do not achieve maximum clinical benefit and suffer from reduced heart function. More than 30 percent of severe AMI patients develop heart failure1 and of those, 50 percent will die within five years.2
TherOx Introduces SuperSaturated Oxygen (SSO2) Therapy
SSO2 Therapy is a novel therapy that complements PCI for acute heart attack. It is designed to restore microvascular blood flow and reduce damage to the heart muscle to improve overall heart function. SSO2 is created using in-hospital oxygen and saline to create a superoxygenated solution, mixing it with the patient’s arterial blood to create superoxygenated blood at up to ten times the normal oxygen content. Immediately following successful PCI, SSO2 Therapy is delivered directly via catheter to the areas of myocardial tissue which may be at risk of permanent loss.
1 Gerber, et al. JAMA Cardiol. 2016;1(2):156-162.
2 Fitch K, et al. The Cost Burden of Worsening Heart Failure in the Medicare Fee for Service Population: An Actuarial Analysis. Milliman Client Report. March 2017.
3 Stone, et al. Circ Cardiovasc Interv. 2009 Oct; 2:366-375. Subset data on file at TherOx, Inc.
SSO2 Therapy has been studied in a series of FDA-sanctioned clinical trials demonstrating a significant reduction in infarct size. For more information on our study data, please visit our Clinical Overview page.
Caution: Federal (United States) law restricts this device to sale by or on the order of a physician.
The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.